All In Biotech

Drug Trial Radar · NCT05769946

A Study of Hemay005 in Adult With Atopic Dermatitis

A Phase II Study to Evaluate the Efficacy and Safety of Hemay005 Tablet in Adult With Moderate to Severe Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: Mar 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

79

Actual

Start

Nov 24, 2022

Primary completion

Jan 24, 2024

Study completion Feb 21, 2024

Sponsor

Sponsor type
Industry
First posted
Mar 15, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A multicenter, randomized, double-blind, placebo-controlled, phase II study to evaluate the efficacy and safety of Hemay005 tablet in the treatment of moderate to severe atopic dermatitis.

Conditions

  • Hemay005, Atopic Dermatitis

Interventions

  • Hemay005Drug

    A PDE-4 inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. EASI-75Time frame: week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • First Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.